Apellis Pharmaceuticals, Inc. · NASDAQ:APLS
Apellis Pharmaceuticals — Q3 2023 Earnings Presentation
11 slides from Apellis Pharmaceuticals's earnings presentation, Nov 1, 2023
Slide 1: Third Quarter 2023 Financial Results Conference Call
Third Quarter 2023 Financial Results Conference Call November 1, 2023
Slide 2: Apellis Participants
Apellis Participants CEDRIC FRANCOIS, M.D., Ph.D. Co-Founder, President & Chief Executive Officer ADAM TOWNSEND Chief Commercial Officer CAROLINE BAUMAL, M.D. Chief Medical Officer T I M O T H Y S U L L I VA N Chief Financial Officer 2
Slide 3: Forward-looking statements
Forward-looking statements Statements in this presentation about future expectations, plans and prospects, as well as any other statements regarding matters that are not historical facts, may constitute “forward-looking statements” within the meaning of The Private Securities Litigation Reform Act o
Slide 4: Delivering on our goals of bringing SYFOVRE and EMPAVELI to patients
Delivering on our goals of bringing SYFOVRE and EMPAVELI to patients ✓ $75M in U.S. net product revenue in 3Q; ✓ $24M in U.S. net product revenue in 3Q; >$160M since launch in March 2023 $67M in 2023 to date ✓ >100,000 vials delivered to HCPs since ✓ 97% compliance rates and zero cases of launch men
Slide 5: Commercial trajectory re-accelerated beginning in August, with strongest weeks to-date in October
Commercial trajectory re-accelerated beginning in August, with strongest weeks to-date in October 2023 weekly rolling 4-week average in commercial vials distributed to physician practices In the third quarter 2023: 4.0K • 37,000 commercial vials and 10,000 samples 3.5K • $75.3 million in U.S. net pr
Slide 6: Demonstrated continued strong EMPAVELI performance
Demonstrated continued strong EMPAVELI performance As of September 30, 2023: >250 patients on therapy 75% of C5 switches from Ultomiris Q3 2023 U.S. ~97% patient compliance rate Net Product Revenue Continued strong formulary access $23.9 Million Growth in treatment-naïve population 6
Slide 7: EMPAVELI Injector is approved!
EMPAVELI Injector is approved! • Enhancing the patient experience in PNH • First-of-its-kind, high-volume injector • Field teams now focused on transitioning existing patients onto EMPAVELI Injector 7 7
Slide 8: Significant presence at recent medical meetings underscores leadership of SYFOVRE in GA
Significant presence at recent medical meetings underscores leadership of SYFOVRE in GA Phase 3 Analyses of SYFOVRE for GA 30-month GALE Extension Study Data Visual Function Analyses Key SYFOVRE • Reduced GA lesion growth with both • Post-hoc microperimetry analysis Data at AAO monthly and EOM treat
Slide 9: Phase 2 NOBLE data: pegcetacoplan reduced disease activity in only 12 weeks
Phase 2 NOBLE data: pegcetacoplan reduced disease activity in only 12 weeks C3c Staining at Week 12 Reduction in C3c staining in pegcetacoplan-treated patients Reduction in intensity % of patients (n=10) ≥ 1+ magnitude 80% ≥ 2+ magnitude 50% Zero staining 40% Baseline (C3c 3+) Week 12 (C3c 0) 9
Slide 10: Consolidated Third Quarter 2023 Financial Results
Consolidated Third Quarter 2023 Financial Results (In USD Millions) Three Months Ended September 30, 2023 2022 EMPAVELI U.S. Net Product Sales $23.9 $17.7 SYFOVRE U.S. Net Product Sales $75.3 -- Licensing and Other Revenue $11.2 $4.4 Total Revenue $110.4 $22.1 Cost of Sales $22.4 $1.4 Expenses R&D E
Slide 11: Third Quarter 2023 Financial Results Conference Call
Third Quarter 2023 Financial Results Conference Call November 1, 2023
Apellis Pharmaceuticals — Q3 2023 Earnings Presentation on 6ix